DD261156A5 - Verfahren zur herstellung von tertiaeren hydroxyalkylxanthinen - Google Patents

Verfahren zur herstellung von tertiaeren hydroxyalkylxanthinen Download PDF

Info

Publication number
DD261156A5
DD261156A5 DD86292595A DD29259586A DD261156A5 DD 261156 A5 DD261156 A5 DD 261156A5 DD 86292595 A DD86292595 A DD 86292595A DD 29259586 A DD29259586 A DD 29259586A DD 261156 A5 DD261156 A5 DD 261156A5
Authority
DD
German Democratic Republic
Prior art keywords
formula
compounds
methyl
radical
group
Prior art date
Application number
DD86292595A
Other languages
German (de)
English (en)
Inventor
Ulrich Gebert
Ismahan Okyayuz-Baklouti
Werner Thorwart
Original Assignee
������@������������k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ������@������������k�� filed Critical ������@������������k��
Publication of DD261156A5 publication Critical patent/DD261156A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
DD86292595A 1985-07-19 1986-07-17 Verfahren zur herstellung von tertiaeren hydroxyalkylxanthinen DD261156A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853525801 DE3525801A1 (de) 1985-07-19 1985-07-19 Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung

Publications (1)

Publication Number Publication Date
DD261156A5 true DD261156A5 (de) 1988-10-19

Family

ID=6276182

Family Applications (1)

Application Number Title Priority Date Filing Date
DD86292595A DD261156A5 (de) 1985-07-19 1986-07-17 Verfahren zur herstellung von tertiaeren hydroxyalkylxanthinen

Country Status (33)

Country Link
US (1) US4833146A (da)
EP (1) EP0268585B1 (da)
JP (1) JPH0788382B2 (da)
KR (1) KR950001019B1 (da)
CN (1) CN1026112C (da)
AR (1) AR244689A1 (da)
AT (1) ATE53211T1 (da)
AU (1) AU588350B2 (da)
BG (1) BG60767B2 (da)
CA (1) CA1262248A (da)
CS (1) CS272766B2 (da)
DD (1) DD261156A5 (da)
DE (2) DE3525801A1 (da)
DK (1) DK157867C (da)
ES (1) ES2001019A6 (da)
FI (1) FI89921C (da)
GR (1) GR861866B (da)
HU (1) HU198486B (da)
IE (1) IE59025B1 (da)
IL (1) IL79457A0 (da)
LT (1) LT3869B (da)
LV (1) LV5703A3 (da)
MA (1) MA20739A1 (da)
MX (1) MX9254A (da)
NO (1) NO165803C (da)
NZ (1) NZ216888A (da)
OA (1) OA08707A (da)
PH (1) PH26262A (da)
PT (1) PT83013B (da)
RU (1) RU2051918C1 (da)
TN (1) TNSN86111A1 (da)
WO (1) WO1987000523A2 (da)
ZA (1) ZA865374B (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
DE3942872A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen
IT1240843B (it) * 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione.
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
DE69119700T2 (de) * 1990-11-07 1996-11-07 Hoechst Roussel Pharma Verwendung von Xanthinen zur Herstellung von Arzneimitteln zur Hemmung der Vermehrung menschlicher Retroviren
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW209834B (da) * 1991-12-11 1993-07-21 Hoechst Ag
EP0557876B1 (de) * 1992-02-22 1996-12-11 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
WO1993017684A2 (en) * 1992-03-04 1993-09-16 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) * 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
WO1995019171A1 (en) * 1994-01-14 1995-07-20 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
CA2183562A1 (en) * 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
DE10042152A1 (de) * 2000-08-26 2002-03-28 Basf Coatings Ag Mit aktinischer Strahlung aktivierbares Thixotropierungsmittel, Verfahren zu seiner Herstellung und seine Verwendung
DE10122390A1 (de) * 2001-05-09 2002-11-28 Basf Coatings Ag Carbamat-und/oder Allophanatgruppen enthaltende, thermisch härtbare, thixotrope Gemische
DE10139262C1 (de) * 2001-08-09 2003-01-02 Basf Coatings Ag Rheologiehilfsmittel, Verfahren zu seiner Herstellung und seine Verwendung
AU2002304685A1 (en) * 2002-04-24 2003-11-10 Basf Coatings Ag Thermally curable, thixotropic mixtures containing carbamate and/or allophanate groups
KR100872788B1 (ko) * 2002-05-28 2008-12-09 엘지전자 주식회사 드럼세탁기
US8686090B2 (en) * 2003-12-10 2014-04-01 Basf Coatings Gmbh Use of urea crystals for non-polymeric coatings
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
EP2265334A2 (en) * 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2262813A4 (en) * 2008-03-31 2011-10-12 Sun Pharmaceutical Ind Ltd IMPROVED PROCESS FOR THE PREPARATION OF MORPHINANE ANALOGS
US8952016B2 (en) 2009-02-27 2015-02-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2012031072A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
IN2014DN08443A (da) 2012-04-13 2015-05-08 Concert Pharmaceuticals Inc

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (fr) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines
DE2335170C2 (de) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
BE795345A (fr) * 1972-02-19 1973-08-13 Albert Ag Chem Werke MEDICAMENT UTILE NOTAMMENT POUR L'IRRIGATION CEREBRALE, PROCEDE DE PREPARATION DE SES MATIERES ACTIVES ET CES MATIERES ElLES-MEMES
CH622519A5 (en) * 1974-07-05 1981-04-15 Hoechst Ag Process for the preparation of hydroxyalkylxanthines
DE2432702C2 (de) * 1974-07-08 1983-01-20 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Hydroxyalkylxanthinen
CA1075690A (en) * 1974-12-13 1980-04-15 Hoechst Aktiengesellschaft Xanthine derivatives
DE3062499D1 (en) * 1979-04-05 1983-05-05 Beecham Wuelfing Gmbh & Co Kg Dialkoxy- and dioxacycloalkyl-alkyltheobromines, pharmaceutical compositions containing them and their preparation
JPS5838284A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
US4575795A (en) * 1983-04-01 1986-03-11 Honeywell Information Systems Inc. Apparatus for detecting a predetermined character of a data string

Also Published As

Publication number Publication date
FI880174A (fi) 1988-01-15
AR244689A1 (es) 1993-11-30
NZ216888A (en) 1989-05-29
AU6143986A (en) 1987-02-10
KR950001019B1 (ko) 1995-02-07
FI89921B (fi) 1993-08-31
NO165803C (no) 1991-04-10
LT3869B (en) 1996-04-25
CA1262248A (en) 1989-10-10
AU588350B2 (en) 1989-09-14
ATE53211T1 (de) 1990-06-15
US4833146A (en) 1989-05-23
DK157867C (da) 1990-07-30
OA08707A (en) 1989-03-31
HU198486B (en) 1989-10-30
LTIP1467A (en) 1995-05-25
JPS63501149A (ja) 1988-04-28
LV5703A3 (lv) 1995-02-20
MX9254A (es) 1993-06-01
ES2001019A6 (es) 1988-04-16
NO871111D0 (no) 1987-03-18
FI89921C (fi) 1993-12-10
IE861917L (en) 1987-01-19
RU2051918C1 (ru) 1996-01-10
TNSN86111A1 (fr) 1990-01-01
DE3671627D1 (de) 1990-07-05
DK139287D0 (da) 1987-03-18
ZA865374B (en) 1987-02-25
EP0268585B1 (de) 1990-05-30
DK139287A (da) 1987-03-18
EP0268585A1 (de) 1988-06-01
NO165803B (no) 1991-01-02
HUT47274A (en) 1989-02-28
DK157867B (da) 1990-02-26
MA20739A1 (fr) 1987-04-01
CS272766B2 (en) 1991-02-12
CS545386A2 (en) 1990-04-11
BG60767B2 (bg) 1996-02-29
CN86105835A (zh) 1987-01-14
IL79457A0 (en) 1986-10-31
PT83013B (pt) 1989-01-30
WO1987000523A2 (en) 1987-01-29
DE3525801A1 (de) 1987-01-22
KR870700623A (ko) 1987-12-30
FI880174A0 (fi) 1988-01-15
PH26262A (en) 1992-04-01
NO871111L (no) 1987-03-18
IE59025B1 (en) 1993-12-15
JPH0788382B2 (ja) 1995-09-27
GR861866B (en) 1986-11-17
PT83013A (de) 1986-08-01
CN1026112C (zh) 1994-10-05
WO1987000523A3 (fr) 1987-02-26

Similar Documents

Publication Publication Date Title
EP0268585B1 (de) Tertiäre hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
DE60002969T2 (de) Imidazo[5,1-f][1,2,4]triazinderivate
DD146708A5 (de) Verfahren zur herstellung von 3-alkylxanthinen
DE2428858A1 (de) 1,3-disubstituierte 2,4(1h,3h)chinazolin-derivate
EP0044928B1 (de) Durch Purinbasen substituierte 1.4;3.6-Dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
DE4013696A1 (de) Salze des azelastins mit verbesserter loeslichkeit
JP2010505747A (ja) Ａ２ａアデノシンレセプタの選択的アンタゴニスト
DE3307395A1 (de) Arzneimittel zur behandlung von schmerzen, fieber, gewebe- und/oder knochen- und gelenkentzuendungen mit einem gehalt an theobromin- oder theophyllinderivaten als aktivem bestandteil
DE2713389A1 (de) Neuartige xanthinverbindungen und dieselben enthaltende pharmazeutische zubereitung
DE2716402A1 (de) 7-(2,3-dihydroxypropyl)-1,3-di-n- propylxanthin, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel
DE3328636A1 (de) Xanthinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0044927B1 (de) Durch Purinbasen substituierte Alkylamino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
JPS63107979A (ja) 新規化合物、その製法及びそれを含む医薬組成物
EP0812844A2 (de) Verwendung von Theophyllinderivaten zur Behandlung und Propylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
EP2159226B1 (de) Antihistamin- und antiallergienmittel sowie verfahren zu seiner herstellung
DE10137038A1 (de) N-3,7 Substituted 1-Methylxanthine Derivates Displaying Inhibitory Activites on Type Five Phosphodiesterase
DE2366501C2 (de) 1-Alkyl-3-methyl-7-oxoalkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
CS272799B2 (en) Method of teriary hydroxylxanthine production
EP0570831A2 (de) Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
DE1770839C3 (de) 7-Chlor-10-(3-dimethylaminopropyl)- benzo [b] [13 eckige Klammer zu naphthyridon-5(10H) und dessen Salze, ein Verfahren zu seiner Herstellung sowie eine pharmazeutische Zubereitung
EP0488079A1 (de) Oxadiazolylmethylpurine, ihre Herstellung und ihre pharmazeutische Verwendung
EP0547508A1 (de) Verwendung von Xanthinderivaten zur Stabilisierung der Gehirndurchblutungsautoregulation
DE1173899B (de) Verfahren zur Herstellung des antiinflammatorisch und analgetisch wirksamen 4-[2'-(ª‰-Dimethylamino-aethoxycarbonyl)-phenylamino]-7-chlor-chinolins
DE19731328A1 (de) Imidazol-Derivate mit Biphenylsulfonylcyanamid-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE1770839B2 (de) 7-chlor-10-(3-dimethylaminopropyl)- benzo eckige klammer auf b eckige klammer zu eckige klammer auf 1,8 eckige klammer zu naphthyridon-5(10h) und dessen salze, ein verfahren zu seiner herstellung sowie eine pharmazeutische zubereitung

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee